financetom
Business
financetom
/
Business
/
UK launches investigation into TikTok, Reddit over children's personal data practices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UK launches investigation into TikTok, Reddit over children's personal data practices
Mar 2, 2025 6:08 PM

March 3 (Reuters) - Britain's privacy watchdog, the

Information Commissioner's Office, on Monday launched an

investigation into how TikTok, Reddit ( RDDT ) and online image

sharing website Imgur safeguard children's privacy.

Social media companies use complex algorithms to prioritise

content and keep users engaged. However, the fact that they

amplify similar content can lead to children being influenced by

increasing amounts of harmful material.

The watchdog said it is probing how ByteDance's short-form

video-sharing platform TikTok uses 13-17-year-olds' personal

information to suggest content in their feed.

Social media platform Reddit ( RDDT ) and Imgur are being investigated

over how they assess the age of their child users, it said.

"If we find there is sufficient evidence that any of these

companies have broken the law, we will put this to them and

obtain their representations before reaching a final

conclusion," the Information Commissioner's Office said in a

statement.

TikTok, Reddit ( RDDT ) and Imgur did not immediately respond to a

Reuters request for comment.

Britain has previously passed legislation that set tougher

rules for social media platforms, including a mandate for them

to prevent children from accessing harmful and age-inappropriate

content by enforcing age limits and age-checking measures.

Social media platforms including Facebook, Instagram and

TikTok are required to "tame" their algorithms to filter out or

downgrade harmful material to help protect children under

proposed British measures published last year.

(Reporting by Angela Christy and Mrinmay Dey in Bengaluru;

Editing by Lincoln Feast.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing settles lawsuits with two 737 MAX crash victims' families
Boeing settles lawsuits with two 737 MAX crash victims' families
Apr 7, 2025
April 7 (Reuters) - U.S. planemaker Boeing ( BA ) settled lawsuits with the families of two victims killed in the March 2019 crash of an Ethiopian Airlines Boeing 737 MAX on the eve of trial, lawyers for the families said. The trial in U.S. District Court in Chicago was set to be the first against the planemaker stemming from...
Neogen Refinances $550 Million Loan, Extends Credit Facility
Neogen Refinances $550 Million Loan, Extends Credit Facility
Apr 7, 2025
10:16 AM EDT, 04/07/2025 (MT Newswires) -- Neogen (NEOG) said Monday it has successfully refinanced its remaining $550 million principal of its $650 million term loan, and its revolving credit facility, originally due in August 2027, by extending the maturity to April 2030. The company said the refinancing includes a $450 million term loan and a $250 million revolving credit...
Germany's big steelmakers call for swift implementation of EU action plan
Germany's big steelmakers call for swift implementation of EU action plan
Apr 7, 2025
DUSSELDORF, April 7 (Reuters) - Thyssenkrupp Steel Europe (TKSE) and Salzgitter on Monday called for the EU Commission's action plan to be implemented as swiftly as possible to shield the sector from U.S. President Donald Trump's tariff measures. Europe must not be left defenceless in the face of growing import pressure, said Gunnar Groebler, CEO of Salzgitter, Germany's second-largest steelmaker,...
Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU
Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU
Apr 7, 2025
10:18 AM EDT, 04/07/2025 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen-Cilag International said Monday it received European Commission approval for its subcutaneous formulation of Rybrevant, or amivantamab, in two indications. The subcutaneous formulation was approved in combination with lazertinib as the first-line treatment for advanced EGFR-mutated non-small cell lung cancer, and as a monotherapy for patients with...
Copyright 2023-2025 - www.financetom.com All Rights Reserved